-

OI Investors: O-I Glass, Inc. Shares Declined By $1.36 On July 29, 2026 ‒ Contact Kirby McInerney LLP to Discuss Your Rights

NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your O-I Glass, Inc. (“O-I Glass” or the “Company”) (NYSE: OI) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until December 28, 2026 to ask the Court to appoint them as lead plaintiff.

[CONTACT THE FIRM IF YOU SUFFERED A LOSS]

What Is The Lawsuit About?

The lawsuit has been filed on behalf of investors who purchased securities during the period of March 14, 2025 through July 28, 2026, inclusive (“the Class Period”). The lawsuit alleges that O-I Glass failed to disclose the true state of the Company’s Fit to Win program, including a delay in achieving its targeted cost savings, higher than expected expenses, operational disruptions that materially offset Fit to Win benefits, and continued competitive and energy-cost pressures affecting its European operations.

On July 28, 2026, O-I Glass announced its second quarter 2026 financial results, substantially reducing its 2026 adjusted EBITDA and free cash flow guidance and realigning its 2027 investor Day financial targets. The Company’s CEO, Gordon J. Hardie, stated, “Achieving our objectives in Europe is taking longer than expected due to persistent market challenges including commercial pressures and higher energy related costs. While we believe these challenges are temporary, we have adjusted our 2026 outlook and realigned our 2027 targets to reflect a more gradual pace of improvement.” Hardie further stated, “Yes, we’ve had a stumble, a chunk of it our own making. We own that. We know how to fix it. We know what the issues are.” On this news, the price of O-I Glass shares declined by $1.36 per share, or approximately 15%, from $9.06 per share on July 28, 2026 to close at $7.70 on July 29, 2026.

[CLICK HERE TO LEARN MORE ABOUT THE LAWSUIT]

What Are My Options?

Courts do not consider applications filed after the relevant deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions. Learn more about the lead plaintiff process and eligibility requirements here.

[WHAT IS A SECURITIES CLASS ACTION?]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found on Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP

NYSE:OI

Release Versions
$Cashtags

Contacts

More News From Kirby McInerney LLP

KGC INVESTORS: Contact Kirby McInerney LLP About the Securities Fraud Lawsuit Filed on Behalf of Kinross Gold Corporation Shareholders

NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP reminds investors who purchased Kinross Gold Corporation (“Kinross” or the “Company”) (NYSE: KGC) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below by January 5, 2027, to discuss your rights or interests in the securities fraud class action at no cost. [CONTACT THE FIRM IF YOU SUFFERED A LOSS] What Is The Lawsuit About? The lawsuit has been filed on behalf of invest...

BIODESIX, INC. BDSX INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 57% Share Drop

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Biodesix, Inc. (“Biodesix” or the “Company”) (NASDAQ: BDSX) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE FIRM’S INVESTIGATION]What Happened?On November 5, 2026, Biodesix announced its third quarter 2026 financial results, reporting third quarte...

CVRX INVESTORS: Contact Kirby McInerney LLP About the Securities Fraud Lawsuit Filed on Behalf of CVRx, Inc. Shareholders

NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP reminds investors who purchased CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below by January 8, 2027, to discuss your rights or interests in the securities fraud class action at no cost.[CONTACT THE FIRM IF YOU SUFFERED A LOSS]What Is The Lawsuit About?The lawsuit has been filed on behalf of investors who purchased...
Back to Newsroom